If you are at all interested or involved in tech transfer, the Tech Transfer Summit North America (TTSNA) is an event you don’t want to miss.
TTSNA is the leading international biotech meeting that fosters licensing, partnering, and technology transfer deals and agreements. Participants can meet members of TTS, Ltd’s global network and have the opportunity to form crucial relationships that will help move their technology transfer offices, biotech companies, and life science projects forward.
This 2-day conference kicks off with a keynote address from Christopher P. Austin, M.D., Director of NIH’s National Center for Advancing Translational Sciences, and includes a keynote from Forma Therapeutics CEO Steven Tregay, who will discuss academic collaborations. Founded in 2008 and approaching $2 billion in pharma deals, including In Vivo 2011 Alliance of the Year nominee, platform based cancer biology and drug discovery company Forma Therapeutics has been listed by FierceBiotech as one of the Fierce 15 most promising private biotechnology companies. Having negotiated deals with Esai, Novartis, Boehringer-Ingelheim, Janssen (JnJ), and Genentech, among others, Tregay will offer up lessons for innovative early stage biotechnology and discuss what Forma’s success and its plans for academic collaborations mean for universities, research institutes and technology transfer offices.
Also on the agenda are Aris Melissaratos, Senior Advisor to the President for Johns Hopkins Enterprise Development (giving a welcome address); Wes Blakeslee, Executive Director of Johns Hopkins Technology Transfer (sitting on a panel), and Elizabeth Good Mazhari, Director of Ventures at Johns Hopkins Technology Transfer (also sitting on a panel).
The summit will feature high-level, interactive panel discussions on TTO’s Real Mandate; IP in the Brave, New, Collaborative World; Financing Biotech; Reducing Clinical Attrition Rates; Translational Medicine: The New Horizon?; One Year Later: How the NIH Repurposing Initiative is Taking Shape; and more.